Skip to main content
. 2021 Nov 16;11(11):e050880. doi: 10.1136/bmjopen-2021-050880

Figure 2.

Figure 2

Barriers to prescribing hydroxyurea: the importance of barriers providers face to prescribing hydroxyurea in sickle cell disease